STANFORD, Calif.- Intel Corporation and the Fred Hutchinson Cancer Research Center today announced a collaborative research effort to apply Intel’s expertise in nanotechnology to develop improved methods of studying, diagnosing and preventing cancer.

The announcement was made at the BioSilico Seminar, held at Stanford University.



“To launch the effort, Intel is building an Intel Raman Bioanalyzer System at the Fred Hutchinson Cancer Research Center in Seattle,” said Andrew Berlin, lead researcher, Intel’s Precision Biology program. “The instrument beams lasers onto tiny medical samples, such as blood serum, to create images that reveal the chemical structure of molecules.



The goal is to determine if this technology, previously used to detect microscopic imperfections on silicon chips, can also detect subtle traces of disease.”



“This collaboration is a unique and exciting interaction,” said Dr. Lee Hartwell, Nobel Laureate and center president and director. “Biologists have never before had such a method for studying the molecular structure of biology.



This is true discovery-based research; we don’t know what we will see or learn. It may lead to a new era of molecular diagnostics and improved methods of early disease detection.”



“Intel enthusiastically endorses Dr. Hartwell’s vision…



Full story here.